NO20034836D0 - Sammensmeltede pyrimidiner som antagonister av kortikotropinfrigivelsesfaktoren (CRF) - Google Patents

Sammensmeltede pyrimidiner som antagonister av kortikotropinfrigivelsesfaktoren (CRF)

Info

Publication number: NO20034836D0
Authority: NO; Norway
Prior art keywords: crf; pyrimidines; antagonists; concentrated; release factor
Prior art date: 2001-04-30

Application number

NO20034836A

Other languages

English (en)

Other versions

NO20034836L (no

Inventor

Anna Maria Capelli

Benedetta Perini

Chiara Marchionni

Yves St-Denis

Fabrizio Micheli

Romano Di Fabio

Alessandra Pasquarello

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-30

Filing date

2003-10-29

Publication date

2003-10-29

2001-04-30 Priority claimed from GB0110570A external-priority patent/GB0110570D0/en

2001-04-30 Priority claimed from GB0110569A external-priority patent/GB0110569D0/en

2001-04-30 Priority claimed from GB0110567A external-priority patent/GB0110567D0/en

2001-07-17 Priority claimed from GB0117401A external-priority patent/GB0117401D0/en

2001-07-17 Priority claimed from GB0117399A external-priority patent/GB0117399D0/en

2001-07-17 Priority claimed from GB0117420A external-priority patent/GB0117420D0/en

2002-02-11 Priority claimed from GB0203201A external-priority patent/GB0203201D0/en

2002-03-22 Priority claimed from GB0206834A external-priority patent/GB0206834D0/en

2003-10-29 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2003-10-29 Publication of NO20034836L publication Critical patent/NO20034836L/no

2003-10-29 Publication of NO20034836D0 publication Critical patent/NO20034836D0/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0465—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Psychiatry (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Epidemiology (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Immunology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)

NO20034836A 2001-04-30 2003-10-29 Sammensmeltede pyrimidiner som antagonister av kortikotropinfrigivelsesfaktoren (CRF) NO20034836D0 (no)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
GB0110570A GB0110570D0 (en)	2001-04-30	2001-04-30	Chemical compounds
GB0110569A GB0110569D0 (en)	2001-04-30	2001-04-30	Chemical compounds
GB0110567A GB0110567D0 (en)	2001-04-30	2001-04-30	Chemical compounds
GB0117401A GB0117401D0 (en)	2001-07-17	2001-07-17	Chemical compounds
GB0117399A GB0117399D0 (en)	2001-07-17	2001-07-17	Chemical compounds
GB0117420A GB0117420D0 (en)	2001-07-17	2001-07-17	Chemical compounds
GB0203201A GB0203201D0 (en)	2002-02-11	2002-02-11	Chemical compounds
GB0206834A GB0206834D0 (en)	2002-03-22	2002-03-22	Chemical compounds
PCT/GB2002/002029 WO2002088095A1 (en)	2001-04-30	2002-04-30	Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)

Publications (2)

Publication Number	Publication Date
NO20034836L NO20034836L (no)	2003-10-29
NO20034836D0 true NO20034836D0 (no)	2003-10-29

Family

ID=27571152

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20034836A NO20034836D0 (no)	2001-04-30	2003-10-29	Sammensmeltede pyrimidiner som antagonister av kortikotropinfrigivelsesfaktoren (CRF)

Country Status (19)

Country	Link
US (1)	US7279474B2 (no)
EP (1)	EP1383747B1 (no)
JP (1)	JP2004528349A (no)
KR (1)	KR20040015206A (no)
CN (1)	CN1649848A (no)
AR (1)	AR033295A1 (no)
AT (1)	ATE386727T1 (no)
AU (1)	AU2002253357B2 (no)
BR (1)	BR0209267A (no)
CA (1)	CA2446514A1 (no)
CZ (1)	CZ20032946A3 (no)
DE (1)	DE60225127T2 (no)
ES (1)	ES2301633T3 (no)
HU (1)	HUP0304054A2 (no)
IL (1)	IL158062A0 (no)
MX (1)	MXPA03009938A (no)
NO (1)	NO20034836D0 (no)
PL (1)	PL366934A1 (no)
WO (1)	WO2002088095A1 (no)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1395591B1 (en) *	2001-06-12	2008-06-04	Glaxo Group Limited	Corticotropin releasing factor antagonists
GB0117396D0 (en) *	2001-07-17	2001-09-05	Glaxo Group Ltd	Chemical compounds
US20070066640A1 (en) *	2003-01-16	2007-03-22	Emiliano Castiglioni	Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
GB0308208D0 (en)	2003-04-09	2003-05-14	Glaxo Group Ltd	Chemical compounds
AU2004235907B2 (en) *	2003-05-05	2007-08-30	F. Hoffmann La-Roche Ag	Fused pyrimidine derivatives with CRF activity
EP1656145A1 (en)	2003-08-12	2006-05-17	F. Hoffmann-La Roche Ag	Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists
CN100398524C (zh) *	2003-08-12	2008-07-02	弗·哈夫曼-拉罗切有限公司	作为crf拮抗剂的四氢喹唑啉衍生物
US7737154B2 (en) *	2003-12-22	2010-06-15	Smithkline Beecham (Cork) Limited	CRF receptor antagonists and methods relating thereto
EP1701961A1 (en) *	2004-01-06	2006-09-20	Taisho Pharmaceutical Co., Ltd	Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group
JP2007526906A (ja) *	2004-03-05	2007-09-20	大正製薬株式会社	ピロロピリミジン誘導体
US7507740B2 (en)	2004-06-02	2009-03-24	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound
EP1781652A1 (en) *	2004-06-25	2007-05-09	Taisho Pharmaceutical Co., Ltd	Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with tetrahydropyridine as crf antagonists
GB0519957D0 (en) *	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
ATE430746T1 (de) *	2004-10-19	2009-05-15	Smithkline Beecham Cork Ltd	Crf-rezeptor-antagonisten und zugehörige verfahren
US8088779B2 (en) *	2005-09-30	2012-01-03	Smithkline Beecham (Cork) Limited	Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
ES2372955T3 (es)	2006-07-06	2012-01-30	Array Biopharma, Inc.	Ciclopenta[d]pirimidinas como inhibidores de la proteína cinasa akt.
WO2008006039A1 (en)	2006-07-06	2008-01-10	Array Biopharma Inc.	Dihydrothieno pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) *	2006-07-06	2011-11-22	Array Biopharma Inc.	Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CA2656566C (en)	2006-07-06	2014-06-17	Array Biopharma Inc.	Dihydrofuro pyrimidines as akt protein kinase inhibitors
CN101511429A (zh) *	2006-07-13	2009-08-19	史密丝克莱恩比彻姆公司	二氢吲哚衍生物和gpr119激动剂
DE102007004303A1 (de)	2006-08-04	2008-02-07	Osram Opto Semiconductors Gmbh	Dünnfilm-Halbleiterbauelement und Bauelement-Verbund
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en)	2007-06-04	2008-12-11	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
KR20150089099A (ko)	2007-07-05	2015-08-04	어레이 바이오파마 인크.	Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US9409886B2 (en)	2007-07-05	2016-08-09	Array Biopharma Inc.	Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
JP5542282B2 (ja) *	2007-07-05	2014-07-09	アレイバイオファーマ、インコーポレイテッド	Ａｋｔプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン
US8846683B2 (en)	2007-07-05	2014-09-30	Array Biopharma, Inc.	Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US8835434B2 (en) *	2008-01-09	2014-09-16	Array Biopharma, Inc.	Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
JP5539225B2 (ja) *	2008-01-09	2014-07-02	アレイバイオファーマ、インコーポレイテッド	Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン
WO2009107767A1 (ja) *	2008-02-29	2009-09-03	大日本住友製薬株式会社	Ｈ４受容体アンタゴニスト作用を有する新規２環性ピリミジン誘導体
WO2009149279A2 (en)	2008-06-04	2009-12-10	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en)	2008-07-16	2019-09-24	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
RU2013148817A (ru)	2011-04-01	2015-05-10	Дженентек, Инк.	Комбинации соединений-ингибиторов акт и мек и способы их применения
WO2012135753A1 (en)	2011-04-01	2012-10-04	Genentech, Inc.	Combinations of akt inhibitor compounds and erlotinib, and methods of use
CN103974955B (zh)	2011-08-23	2018-06-19	阿萨纳生物科技有限责任公司	嘧啶并-哒嗪酮化合物及其用途
CN107652289B (zh)	2012-06-13	2020-07-21	因塞特控股公司	作为fgfr抑制剂的取代的三环化合物
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
WO2014151200A2 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
WO2014145576A2 (en)	2013-03-15	2014-09-18	Northwestern University	Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
EP2970384A1 (en)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
KR102269032B1 (ko)	2013-04-19	2021-06-24	인사이트 홀딩스 코포레이션	Fgfr 저해제로서 이환식 헤테로사이클
CN104193745B (zh) *	2014-07-30	2016-09-28	斯芬克司药物研发（天津）股份有限公司	一种咪唑并嘧啶羧酸类化合物及其制备方法
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
PE20171514A1 (es)	2015-02-20	2017-10-20	Incyte Corp	Heterociclos biciclicos como inhibidores de fgfr
KR20190140011A (ko)	2017-04-28	2019-12-18	아사나 바이오사이언시스 엘엘씨	아토피성 피부염을 치료하고, 활성 약학적 성분의 안정성을 개선하기 위한 제형물, 방법, 키트, 및 투여형
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CA3094609A1 (en)	2018-04-09	2019-10-17	Raqualia Pharma Inc.	Fused cyclic urea derivatives as crhr2 antagonist
SG11202010636VA (en)	2018-05-04	2020-11-27	Incyte Corp	Solid forms of an fgfr inhibitor and processes for preparing the same
BR112020022373A2 (pt)	2018-05-04	2021-02-02	Incyte Corporation	sais de um inibidor de fgfr
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021076602A1 (en)	2019-10-14	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
JP7720840B2 (ja)	2019-12-04	2025-08-08	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての三環式複素環
CN115151539A (zh)	2019-12-04	2022-10-04	因赛特公司	Fgfr抑制剂的衍生物
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
EP4161523A4 (en) *	2020-06-03	2024-07-03	Yumanity Therapeutics, Inc.	BICYCLIC HETEROARENES AND METHODS OF USE THEREOF
US12065494B2 (en)	2021-04-12	2024-08-20	Incyte Corporation	Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
AR126102A1 (es)	2021-06-09	2023-09-13	Incyte Corp	Heterociclos tricíclicos como inhibidores de fgfr
CA3220155A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9022644D0 (en)	1990-10-18	1990-11-28	Ici Plc	Heterocyclic compounds
TW574214B (en) *	1994-06-08	2004-02-01	Pfizer	Corticotropin releasing factor antagonists
US6403599B1 (en)	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
TW477787B (en) *	1996-08-27	2002-03-01	Pfizer	Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
JP2000038350A (ja)	1998-05-18	2000-02-08	Yoshitomi Pharmaceut Ind Ltd	糖尿病治療薬
EP1040831A3 (en)	1999-04-02	2003-05-02	Pfizer Products Inc.	Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
US6387894B1 (en)	1999-06-11	2002-05-14	Pfizer Inc.	Use of CRF antagonists and renin-angiotensin system inhibitors
US6432989B1 (en) *	1999-08-27	2002-08-13	Pfizer Inc	Use of CRF antagonists to treat circadian rhythm disorders
CN1390219A (zh)	1999-09-17	2003-01-08	艾博特股份有限两合公司	作为治疗剂的吡唑并嘧啶类
PL354784A1 (en)	1999-09-30	2004-02-23	Neurogen Corporation	Certain alkylene diamine-substituted heterocycles
IL139197A0 (en) *	1999-10-29	2001-11-25	Pfizer Prod Inc	Use of corticotropin releasing factor antagonists and related compositions
EP1149583A3 (en)	2000-04-13	2001-11-14	Pfizer Products Inc.	Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues

2002
- 2002-04-30 ES ES02722478T patent/ES2301633T3/es not_active Expired - Lifetime
- 2002-04-30 DE DE60225127T patent/DE60225127T2/de not_active Expired - Fee Related
- 2002-04-30 CZ CZ20032946A patent/CZ20032946A3/cs unknown
- 2002-04-30 AT AT02722478T patent/ATE386727T1/de not_active IP Right Cessation
- 2002-04-30 IL IL15806202A patent/IL158062A0/xx unknown
- 2002-04-30 WO PCT/GB2002/002029 patent/WO2002088095A1/en not_active Ceased
- 2002-04-30 HU HU0304054A patent/HUP0304054A2/hu unknown
- 2002-04-30 CA CA002446514A patent/CA2446514A1/en not_active Abandoned
- 2002-04-30 MX MXPA03009938A patent/MXPA03009938A/es active IP Right Grant
- 2002-04-30 AU AU2002253357A patent/AU2002253357B2/en not_active Ceased
- 2002-04-30 EP EP02722478A patent/EP1383747B1/en not_active Expired - Lifetime
- 2002-04-30 US US10/476,368 patent/US7279474B2/en not_active Expired - Fee Related
- 2002-04-30 PL PL02366934A patent/PL366934A1/xx not_active Application Discontinuation
- 2002-04-30 KR KR10-2003-7014160A patent/KR20040015206A/ko not_active Withdrawn
- 2002-04-30 AR ARP020101597A patent/AR033295A1/es unknown
- 2002-04-30 JP JP2002585397A patent/JP2004528349A/ja active Pending
- 2002-04-30 BR BR0209267-0A patent/BR0209267A/pt not_active IP Right Cessation
- 2002-04-30 CN CNA028107462A patent/CN1649848A/zh active Pending
2003
- 2003-10-29 NO NO20034836A patent/NO20034836D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20034836L (no)	2003-10-29
KR20040015206A (ko)	2004-02-18
CA2446514A1 (en)	2002-11-07
JP2004528349A (ja)	2004-09-16
US20040176400A1 (en)	2004-09-09
CN1649848A (zh)	2005-08-03
EP1383747A1 (en)	2004-01-28
MXPA03009938A (es)	2005-09-07
US7279474B2 (en)	2007-10-09
AU2002253357B2 (en)	2006-08-24
WO2002088095A1 (en)	2002-11-07
HUP0304054A2 (hu)	2004-04-28
IL158062A0 (en)	2004-03-28
AR033295A1 (es)	2003-12-10
EP1383747B1 (en)	2008-02-20
BR0209267A (pt)	2004-06-15
CZ20032946A3 (en)	2004-05-12
PL366934A1 (en)	2005-02-07
ATE386727T1 (de)	2008-03-15
DE60225127T2 (de)	2009-02-19
ES2301633T3 (es)	2008-07-01
DE60225127D1 (en)	2008-04-03

Publication	Publication Date	Title
NO20034836D0 (no)	2003-10-29	Sammensmeltede pyrimidiner som antagonister av kortikotropinfrigivelsesfaktoren (CRF)
HUS1500055I1 (hu)	2016-03-29	HIV-gátló pirimidinszármazékok
EP1546115A4 (en)	2010-08-04	Substituted pyrimidines
DK1417180T3 (da)	2007-04-10	Fremstilling af aminopyrimidinforbindelser
IS7287A (is)	2004-05-26	Pýrimídín efnasambönd
DK1487805T3 (da)	2012-10-15	Pyrimidinderivater
DK1669092T3 (da)	2010-07-12	Tilberedning til profylakse af restenose
DE60336092D1 (de)	2011-03-31	Verfahren zur Herstellung substituierter Pyrimidine
NO20042680L (no)	2004-06-25	Fremgangsmater for fremstilling av O-demetylvenflaxine
DK1549652T3 (da)	2009-02-23	Kondenserede azolpyrimidinderivater
NO20024508D0 (no)	2002-09-20	Bygningskomponenter av kompositt
DK1762567T3 (da)	2012-06-25	Pyrazolderivater til behandling af HIV
IS6868A (is)	2003-07-08	Ný pýrimidínefnasambönd
DK1373256T3 (da)	2005-10-10	CCR5-antagonister, der er nyttige til behandling af AIDS
DK1309545T3 (da)	2007-10-29	Fremgangsmåde til fremstilling af alkylarylsulfonater
DE60205921D1 (de)	2005-10-06	SUBSTITUIERTE 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDOç1,2-A!PYRIMIDIN-4-ON- UND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO-ç1,2-A!PYRIMIDIN-5(1H)ONDERIVATE
DK1840125T3 (da)	2009-11-09	Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
ECSP055888A (es)	2005-09-20	Derivados de aril-quinazolin/aril-2-amino-fenil metanona que promueven la liberación de la hormona paratiroides.
DK1401451T3 (da)	2010-03-29	Quinazolinderivater, der fremmer frigivelsen af parathyroidhormon
DK1503995T3 (da)	2008-04-21	Fremgangsmåde til fremstilling af substituerede phenylsulfonylurinstoffer
DK1511724T3 (da)	2014-06-16	Fremgangsmåde til fremstilling af thioalkylaminderivater
DK1392711T3 (da)	2014-06-10	Fremgangsmåde til fremstilling af xylose
DK1699794T3 (da)	2008-05-19	Fremgangsmåde til fremstilling af triazolpyrimidiner
ATE297927T1 (de)	2005-07-15	Substituierte 3,4-dihydro-pyrido(1,2-a)pyrimidine
HK1063312A (en)	2004-12-24	Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)

Legal Events

Date	Code	Title	Description
2007-11-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application